

10/544254

JC09 Rec'd PCT/PTO 01 AUG 2005

Date: August 1, 2005 Label No. EV710701695US I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Donald S. Prater
Name (Print)

Donald S. Prater
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Miyazaki et al.)	Examiner:	Unassigned
)		
Application No.:	Unassigned)	Group Art Unit:	Unassigned
)		
Filed:	August 1, 2005)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-081)	Customer No.:	33432

For: MEDICAMENT FOR PREVENTING, INHIBITING OR TREATING ADHESION FORMATION

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 1, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following the filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear on the first page of any patent to issue therefrom.

10/54254

Information Disclosure Statement
U.S. Patent Application No. Unassigned

JC09 Rec'd PCT/PTO 01, AUG 2005

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-081
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO/SB/08 w/5 Documents

10/15 44254
JC09 Rec'd PCT/PTO 01 AUG 2005
PTO-508a (05-06)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	Unassigned
				Filing Date	August 1, 2005
				First Named Inventor	Miyazaki et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	3190-081

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.		
		OKAMOTO, et al., "Chymase Inhibitors May Prevent Postoperative Adhesion Formation," Fertility and Sterility, May 2002, pp. 1044-1048, Vol. 77, No. 5.		
		OKAMOTO et al., "Chymase Inhibitor Suppresses Adhesion Formation in a Hamster Experimental Model," European Journal of Pharmacology, 2002, pp. 265-267, Vol. 435.		
		OKAMOTO et al., "Chymase Inhibitor, BCEAB, Suppressed Peritoneal Adhesion Formation in Hamster," Journal of Surgical Research, 2002, pp. 219-222, Vol. 107.		
		OKAMOTO et al., "Oral Administration of a Novel Chymase Inhibitor, NK 3201, Prevents Peritoneal Adhesion Formation in Hamsters," Jpn. J. Pharmacol. 2002, pp. 94-96, Vol. 90.		
		International Search Report for PCT/JP2004/001111, dated May 11, 2004		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.